SNY: Japan Approves Wayrilz
Sanofi's Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia based on the LUNA 3 Phase 3 study
Sanofi Says Japan Approves Wayrilz For Persistent Or Chronic Immune Thrombocytopenia Based On LUNA 3 Phase 3 Study